INTRODUCTION: Data on the characteristics of female patients counselled for fertility preservation and the efficacy and risk of the applied procedures are still poor. We therefore analysed the registry of a network of 70 infertility centers which are involved in fertility preservation in Germany, Switzerland and Austria, called FertiPROTEKT ( hhtp://www.fertiprotekt.eu ). MATERIALS AND METHODS: 1,280 counselled patients (15-40 years) were analysed regarding characteristics and different fertility preservation treatments before cytotoxic therapy in 2007-2009. RESULTS: 34.8% of the counselled patients were diagnosed with breast cancer, 30.5% with Hodgkin's lymphoma, 25.4% with other malignancies and 9.3% with non-malignant diseases. 89.6% of the treated breast cancer patients were 25-40 years of age, and 87.5% of the lymphoma patients were 15-30 years of age. At the time of counselling, 85.3% of the breast cancer patients and 92.7% of the lymphoma patients were childless. 1,080 patients received a single or combined therapy such as GnRH agonists (n = 823), cryopreservation of ovarian tissue (n = 500), ovarian stimulation (n = 221) and transposition of the ovaries (n = 24). Only one severe complication, requiring postponement of the chemotherapy, was documented. In stimulated patients, 2,417 oocytes (mean n = 11.6, SD ± 7.7) were received. Fertilisation rate per received oocyte was 61.3%. CONCLUSIONS: Fertility preservation programmes mainly involve women without children, diagnosed with breast cancer or Hodgkin's lymphoma. Fertility preservation techniques can be applied with low risk. The limited and age-dependant success rate of the different therapies require individualised approaches of single or combined fertility preservation techniques.
INTRODUCTION: Data on the characteristics of female patients counselled for fertility preservation and the efficacy and risk of the applied procedures are still poor. We therefore analysed the registry of a network of 70 infertility centers which are involved in fertility preservation in Germany, Switzerland and Austria, called FertiPROTEKT ( hhtp://www.fertiprotekt.eu ). MATERIALS AND METHODS: 1,280 counselled patients (15-40 years) were analysed regarding characteristics and different fertility preservation treatments before cytotoxic therapy in 2007-2009. RESULTS: 34.8% of the counselled patients were diagnosed with breast cancer, 30.5% with Hodgkin's lymphoma, 25.4% with other malignancies and 9.3% with non-malignant diseases. 89.6% of the treated breast cancerpatients were 25-40 years of age, and 87.5% of the lymphomapatients were 15-30 years of age. At the time of counselling, 85.3% of the breast cancerpatients and 92.7% of the lymphomapatients were childless. 1,080 patients received a single or combined therapy such as GnRH agonists (n = 823), cryopreservation of ovarian tissue (n = 500), ovarian stimulation (n = 221) and transposition of the ovaries (n = 24). Only one severe complication, requiring postponement of the chemotherapy, was documented. In stimulated patients, 2,417 oocytes (mean n = 11.6, SD ± 7.7) were received. Fertilisation rate per received oocyte was 61.3%. CONCLUSIONS: Fertility preservation programmes mainly involve women without children, diagnosed with breast cancer or Hodgkin's lymphoma. Fertility preservation techniques can be applied with low risk. The limited and age-dependant success rate of the different therapies require individualised approaches of single or combined fertility preservation techniques.
Authors: Sally A Dominick; Brian W Whitcomb; Jessica R Gorman; Jennifer E Mersereau; Karine Chung; H Irene Su Journal: J Cancer Surviv Date: 2014-05-24 Impact factor: 4.442
Authors: A Balduzzi; J-H Dalle; K Jahnukainen; M von Wolff; G Lucchini; M Ifversen; K T Macklon; C Poirot; T Diesch; A Jarisch; D Bresters; I Yaniv; B Gibson; A M Willasch; R Fadini; L Ferrari; A Lawitschka; A Ahler; N Sänger; S Corbacioglu; M Ansari; R Moffat; A Dalissier; E Beohou; P Sedlacek; A Lankester; C D De Heredia Rubio; K Vettenranta; J Wachowiak; A Yesilipek; E Trigoso; T Klingebiel; C Peters; P Bader Journal: Bone Marrow Transplant Date: 2017-07-24 Impact factor: 5.483
Authors: Ruba A Akel; Xiaoyue M Guo; Molly B Moravek; Rafael Confino; Kristin N Smith; Angela K Lawson; Susan C Klock; Edward J Tanner Iii; Mary Ellen Pavone Journal: J Adolesc Young Adult Oncol Date: 2020-01-10 Impact factor: 2.223
Authors: L Bastings; J Liebenthron; J R Westphal; C C M Beerendonk; H van der Ven; B Meinecke; M Montag; D D M Braat; R Peek Journal: J Assist Reprod Genet Date: 2014-06-14 Impact factor: 3.412
Authors: K Kyono; T Hashimoto; M Toya; M Koizumi; C Sasaki; S Shibasaki; N Aono; Y Nakamura; R Obata; N Okuyama; Y Ogura; H Igarashi Journal: J Assist Reprod Genet Date: 2017-09-02 Impact factor: 3.412
Authors: Patricia E Hershberger; Lorna Finnegan; Susan Altfeld; Sara Lake; Jennifer Hirshfeld-Cytron Journal: Res Theory Nurs Pract Date: 2013 Impact factor: 0.688